Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

BioNTech already owned part of InstaDeep as ... hub in Asia – located initially in Taiwan – along with an mRNA manufacturing unit in Singapore, according to the company's JPM update.

The acquisition also beefs up BioNTech's R&D and manufacturing capabilities in China, adding over 300 Biotheus employees to its ranks. It's a bold move aimed at dominating a high-potential market.

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid ...

Dec 27 (Reuters) - BioNTech (22UAy.DE), opens new tab has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other ...

Truist sets BioNTech's price target at $172, highlighting BNT327's revenue potential of $6B+ across multiple cancer indications. BioNTech's BNT327 could lead U.S. and European approvals for key ...

More about BioNTech SE BioNTech SE is a biotechnology company primarily focused on developing and manufacturing immunotherapies for the treatment of cancer and infectious diseases. The company is well ...

BioNTech may be deeply ensconced in the latter ... protein engineering, manufacturing and supply chain. One of the main research areas for the new lab will be the development of new vaccines ...

Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...